Share this article
Share this article
CRANFORD, N.J., April 29, 2021 /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius or the Company ) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok
® Phase 3 trial-related webinar. Mino-Lok
®, the Company s lead product candidate, is an antibiotic lock therapy designed to salvage central venous catheters (CVCs) in patients with catheter related bloodstream infections (CRBSIs) or central line associated blood stream infections (CLABSIs). The webinar, led by Dr. Alan Lader, PhD, Vice President of Clinical Operations at Citius Pharmaceuticals was attended by investigators, clinical trial staff and referring physicians from trial sites participating in the Mino-Lok Phase 3 clinical trial.
University of New Mexico
VA Sierra Nevada Health Care System
A few key topics on the agenda included a review of the pathogens encountered to date, the benefits of Mino-Lok for a CLABSI patient with a mucosal barrier injury, the frequency of unnecessary removal of non-colonized CVCs in suspected CLABSI patients with bacteremia, how to handle patients with multiple catheters (case history), and the path forward for study completion. Currently, the primary treatment for patients who become bacteremic because of the central lines being infected is to treat the patient aggressively with culture-directed antibiotics and to remove the central line which is believed to be the source of the infection and replaced when the patient s status improves. Patients and physicians need an effective and less invasive alternative to catheter exchange which utilizes much of the same set of resources needed to treat Covid-19 patients, especially in the ICU. We have been fortunate to be able to perse